About GA-binding protein alpha chain
GA-binding protein alpha chain (GABPA) is a protein
from Homo sapiens identified by UniProt accession
Q06546, 454 residues long.
MolForge cross-references it against 0 known binders and
159 disease associations.
Target properties
| Protein name | GA-binding protein alpha chain |
| UniProt accession | Q06546 |
| Gene | GABPA |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (159)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.10
- breast cancer · score 0.08
- hepatocellular carcinoma · score 0.08
- nonpapillary renal cell carcinoma · score 0.07
- Syndactyly type 2 · score 0.07
- erythrocyte count · score 0.07
- Crigler-Najjar syndrome type 2 · score 0.06
- pachyonychia congenita · score 0.06
- syndactyly type 4 · score 0.06
- schizophrenia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q06546-F1 | alphafold | PREDICTED | 67.72 | — |
Amino-acid sequence (454 residues)
MTKREAEELI EIEIDGTEKA ECTEESIVEQ TYAPAECVSQ AIDINEPIGN LKKLLEPRLQ CSLDAHEICL QDIQLDPERS LFDQGVKTDG TVQLSVQVIS YQGIEPKLNI LEIVKPADTV EVVIDPDAHH AESEAHLVEE AQVITLDGTK HITTISDETS EQVTRWAAAL EGYRKEQERL GIPYDPIQWS TDQVLHWVVW VMKEFSMTDI DLTTLNISGR ELCSLNQEDF FQRVPRGEIL WSHLELLRKY VLASQEQQMN EIVTIDQPVQ IIPASVQSAT PTTIKVINSS AKAAKVQRAP RISGEDRSSP GNRTGNNGQI QLWQFLLELL TDKDARDCIS WVGDEGEFKL NQPELVAQKW GQRKNKPTMN YEKLSRALRY YYDGDMICKV QGKRFVYKFV CDLKTLIGYS AAELNRLVTE CEQKKLAKMQ LHGIAQPVTA VALATASLQT EKDN
Explore GA-binding protein alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets